Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Net Cash Flow (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Net Cash Flow for 17 consecutive years, with -$5.5 billion as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 311.96% to -$5.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$324.0 million through Dec 2025, up 68.7% year-over-year, with the annual reading at -$324.0 million for FY2025, 68.7% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$5.5 billion at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • The five-year high for Net Cash Flow was $3.9 billion in Q4 2023, with the low at -$5.5 billion in Q4 2025.
  • Average Net Cash Flow over 5 years is -$236.2 million, with a median of -$116.0 million recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 570.92% in 2021, then plummeted 2768.97% in 2022.
  • Over 5 years, Net Cash Flow stood at $491.0 million in 2021, then surged by 159.27% to $1.3 billion in 2022, then skyrocketed by 204.24% to $3.9 billion in 2023, then tumbled by 32.84% to $2.6 billion in 2024, then tumbled by 311.96% to -$5.5 billion in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$5.5 billion, $3.1 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.